Pulmonary exacerbations aren’t only traumatic for patients and their relatives, but also costly to treat. We are grateful for the support of this trial by the patients and clinicians, reflecting the great interest in finding an effective treatment for this serious respiratory disease, said Igor Gonda, Aradigm’s president and CEO. Our partnering discussions and interactions with FDA will today intensify with the goal to work jointly to make this promising therapy available for this underserved orphan patient population. .. Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study Aradigm Corporation today announced positive best series data from its recently concluded 6-month Phase 2b study with Aradigm’s once-daily dual discharge ciprofloxacin for inhalation in individuals with non-cystic fibrosis bronchiectasis.This article can be republished with kind authorization from our close friends at The Kaiser Family members Foundation. You will see the entire Kaiser Daily Health Policy Statement, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Kaiser Daily Wellness Policy Report is released for Kaisernetwork.org, a free of charge provider of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Table Kaiser and Company Family Foundation. All rights reserved.
Chinese Medical Association, Copyright Clearance Center announce agreement Copyright Clearance Middle, Inc. , a not-for-profit organization and leading provider of licensing solutions, announces an agreement with the Chinese Medical Association , the largest medical journal publisher in China.